Literature DB >> 29661825

NKp46 Calibrates Tumoricidal Potential of Type 1 Innate Lymphocytes by Regulating TRAIL Expression.

Gleb Turchinovich1,2, Stefan Ganter3, Anne Bärenwaldt3,2, Daniela Finke3,2.   

Abstract

NK cells are a subset of group 1 innate lymphocytes that recognize and eliminate virus-infected and transformed cells. During the course of their development, NK cells acquire a repertoire of activating and inhibitory receptors, which ultimately define their reactivity against target cells. The array of receptors and their specificity during early developmental stages will control and imprint functional properties of NK cells, a process known as "NK cell education." Innate lymphoid cells (ILCs) are a diverse group of lymphocytes, which, like NK cells, do not rely on somatically rearranged Ag receptors for recognition. Among ILC subsets, ILC1s are most like NK cells functionally. Prototypic ILC1s reside in the liver, and a large part of their function is attributed to the expression of TRAIL, a TNF superfamily member with a well-documented antitumor activity. In this article, we show that TRAIL expression on mouse ILC1s is controlled by an activating receptor NKp46, which has been previously shown to control NK cell education. In the absence of NKp46, ILC1s fail to express normal levels of TRAIL on the surface, which results in diminished cytotoxicity toward TRAIL receptor-positive targets. To our knowledge, these findings provide the first evidence of a role of NKp46 in ILC1s that calibrates their antitumor response.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29661825     DOI: 10.4049/jimmunol.1701333

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML.

Authors:  Bérengère Salomé; Alejandra Gomez-Cadena; Romain Loyon; Madeleine Suffiotti; Valentina Salvestrini; Tania Wyss; Giulia Vanoni; Dan Fu Ruan; Marianna Rossi; Alessandra Tozzo; Paolo Tentorio; Elena Bruni; Carsten Riether; Eva-Maria Jacobsen; Peter Jandus; Curdin Conrad; Manfred Hoenig; Ansgar Schulz; Katarzyna Michaud; Matteo Giovanni Della Porta; Silvia Salvatore; Ping-Chih Ho; David Gfeller; Adrian Ochsenbein; Domenico Mavilio; Antonio Curti; Emanuela Marcenaro; Alexander Steinle; Amir Horowitz; Pedro Romero; Sara Trabanelli; Camilla Jandus
Journal:  Blood Adv       Date:  2019-11-26

2.  Inflammation-Induced Lactate Leads to Rapid Loss of Hepatic Tissue-Resident NK Cells.

Authors:  Garvin Dodard; Angela Tata; Timothy K Erick; Diego Jaime; S M Shahjahan Miah; Linda Quatrini; Bertrand Escalière; Sophie Ugolini; Eric Vivier; Laurent Brossay
Journal:  Cell Rep       Date:  2020-07-07       Impact factor: 9.423

Review 3.  Ambiguous roles and potential therapeutic strategies of innate lymphoid cells in different types of tumor.

Authors:  Shijie Wang; Pin Wu; Yongyuan Chen; Ying Chai
Journal:  Oncol Lett       Date:  2020-06-16       Impact factor: 2.967

Review 4.  Deconstructing deployment of the innate immune lymphocyte army for barrier homeostasis and protection.

Authors:  Francisca F Almeida; Nicolas Jacquelot; Gabrielle T Belz
Journal:  Immunol Rev       Date:  2018-11       Impact factor: 12.988

Review 5.  The Natural Cytotoxicity Receptors in Health and Disease.

Authors:  Alexander David Barrow; Claudia Jane Martin; Marco Colonna
Journal:  Front Immunol       Date:  2019-05-07       Impact factor: 7.561

Review 6.  Interactions of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) with the Immune System: Implications for Inflammation and Cancer.

Authors:  Katharina Beyer; Ann-Kathrin Baukloh; Ani Stoyanova; Carsten Kamphues; Arne Sattler; Katja Kotsch
Journal:  Cancers (Basel)       Date:  2019-08-13       Impact factor: 6.639

Review 7.  Innate lymphocytes: pathogenesis and therapeutic targets of liver diseases and cancer.

Authors:  Yongyan Chen; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2020-10-12       Impact factor: 11.530

8.  Innate lymphoid cells control signaling circuits to regulate tissue-specific immunity.

Authors:  Christoph S N Klose; David Artis
Journal:  Cell Res       Date:  2020-05-06       Impact factor: 25.617

9.  Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic target.

Authors:  Said Farschtschi; Lan Kluwe; Su-Jin Park; Su-Jun Oh; Nancy Mah; Victor-Felix Mautner; Andreas Kurtz
Journal:  Cancer Immunol Immunother       Date:  2020-03-19       Impact factor: 6.968

Review 10.  NK Cell Development in Times of Innate Lymphoid Cell Diversity.

Authors:  Vladislava Stokic-Trtica; Andreas Diefenbach; Christoph S N Klose
Journal:  Front Immunol       Date:  2020-07-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.